Latest Breaking News On - Ingrezza sprinkle - Page 1 : vimarsana.com

Managing Tardive Dyskinesia: New Data from Phase 3 Study of Ingrezza

Check out new data from phase 3 study of Ingrezza for the real-world management of tardive dyskinesia.

FDA Clears Ingrezza Sprinkle for Bipolar-Linked Tardive Dyskinesia

FDA Approves New Ingrezza Formulation for Patients Who Have Difficulty Swallowing

Each Ingrezza Sprinkle capsule contains oral granules consisting of valbenazine, a vesicular monoamine transporter 2 inhibitor.

Ingrezza Sprinkle Capsules Received FDA Approval for Tardive Dyskinesia in Adults

The new formulation was approved to help patients with tardive dyskinesia who have trouble swallowing.

Neurocrine Biosciences' Huntington's disease drug gets FDA approval

By Sruthi Narasimha Chari (Reuters) -The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tu...

FDA Approves New Ingrezza Formulation for Patients Who Have Difficulty Swallowing

Each Ingrezza Sprinkle capsule contains oral granules consisting of valbenazine, a vesicular monoamine transporter 2 inhibitor.

New E. Coli Outbreak; How ECMO Redefines Death; A Step Closer to Universal Blood

Health news and commentary gathered by <em>MedPage Today</em> staff

Neurocrine bags FDA approval for new 'sprinkle' Ingrezza formulation

The sprinkle formulation of Ingrezza is approved as an alternative for Huntington’s patients who have difficulty swallowing.